145 related articles for article (PubMed ID: 22214432)
1. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
Abbas N; Heyerdahl H; Bruland OS; Borrebæk J; Nesland J; Dahle J
EJNMMI Res; 2011 Aug; 1(1):18. PubMed ID: 22214432
[TBL] [Abstract][Full Text] [Related]
2. Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.
Abbas N; Heyerdahl H; Bruland ØS; Brevik EM; Dahle J
Curr Radiopharm; 2013 Jun; 6(2):78-86. PubMed ID: 23551110
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
4. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
[TBL] [Abstract][Full Text] [Related]
5. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
[TBL] [Abstract][Full Text] [Related]
6. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Dahle J; Bruland OS; Larsen RH
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
[TBL] [Abstract][Full Text] [Related]
7. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
8. [
Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
[TBL] [Abstract][Full Text] [Related]
9. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
Dahle J; Borrebaek J; Melhus KB; Bruland OS; Salberg G; Olsen DR; Larsen RH
Nucl Med Biol; 2006 Feb; 33(2):271-9. PubMed ID: 16546683
[TBL] [Abstract][Full Text] [Related]
10. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.
Dahle J; Jonasdottir TJ; Heyerdahl H; Nesland JM; Borrebaek J; Hjelmerud AK; Larsen RH
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):93-102. PubMed ID: 19593562
[TBL] [Abstract][Full Text] [Related]
11. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
12. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
13. 227Th-EDTMP: a potential therapeutic agent for bone metastasis.
Washiyama K; Amano R; Sasaki J; Kinuya S; Tonami N; Shiokawa Y; Mitsugashira T
Nucl Med Biol; 2004 Oct; 31(7):901-8. PubMed ID: 15464392
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
15. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
Melhus KB; Larsen RH; Stokke T; Kaalhus O; Selbo PK; Dahle J
Cancer Biother Radiopharm; 2007 Aug; 22(4):469-79. PubMed ID: 17803441
[TBL] [Abstract][Full Text] [Related]
17. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
19. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
[TBL] [Abstract][Full Text] [Related]
20. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
Heyerdahl H; Røe K; Brevik EM; Dahle J
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):153-9. PubMed ID: 23790511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]